NCT07418918
Completed
Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Lactobacillus Bicomponent Viable Capsules for Vaginal Use in the Treatment of Bacterial Vaginosis
Guangdong Longchuangji Pharmaceutical Co., Ltd.1 site in 1 country66 target enrollmentStarted: January 3, 2023Last updated:
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Guangdong Longchuangji Pharmaceutical Co., Ltd.
- Enrollment
- 66
- Locations
- 1
- Primary Endpoint
- Clinical Cure Rate
Overview
Brief Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase IIb clinical study, to evaluate the efficacy and safety of the dual - live Lactobacilli-containing vaginal capsule for the treatment of bacterial vaginosis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
This trial employs a double-blind method, meaning that neither the investigator nor the subject knows which treatment the subject is receiving. Both the Vaginal Lactobacillus Dual Probiotic Capsules used in the treatment group and the placebo used in the placebo group are provided by Guangdong Longchuangji Pharmaceutical Co., Ltd. The investigational drug and the control drug are nearly identical in appearance, shape, specification, and dosage.
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The subject fully understands the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily participates in the study, and provides written informed consent prior to trial commencement;
- •Female aged 18 to 50 years (inclusive of the boundary values);
- •History of sexual activity, willing to undergo vaginal administration of medication, and agrees to refrain from using other intravaginal products (e.g., contraceptive creams, gels, foams, sponges, lubricants, douches, tampons, etc.) and from engaging in sexual activity throughout the entire trial period;
- •Has a normal and regular menstrual cycle;
- •Clinically diagnosed with bacterial vaginosis (BV), defined as having at least three positive findings on Amsel's criteria, including the presence of clue cells (i.e., clue cells accounting for \>20% of the total vaginal epithelial cells); and a Nugent score ≥ 7 points.
Exclusion Criteria
- •Known allergy to any component of the investigational drug;
- •Known current diagnosis of pelvic inflammatory disease, cervicitis, or acute urogenital infection;
- •Vulvovaginitis due to other infectious etiologies, such as vulvovaginal candidiasis (VVC), trichomonal vaginitis (TV), aerobic vaginitis (AV score ≥5), gonorrhea, or Chlamydia trachomatisinfection,etc;
- •Pelvic examination at screening reveals the presence of condyloma acuminata (genital warts);
- •History of complicated or recurrent VVC within 1 year prior to screening;
- •Known diagnosis of uterine fibroids or adenomyosis requiring intervention as assessed by the investigator;
- •Vaginal speculum examination at screening indicates significant vaginal mucosal injury (e.g., mucosal edema, ulceration, erosion);
- •History of significant diseases affecting the cardiovascular, hepatic, renal, pulmonary, gastrointestinal, neurological, metabolic, urogenital, endocrine, or psychiatric systems, which in the investigator's judgment may compromise subject safety;
- •Use of vaginal douching or other intravaginal treatments (e.g., products such as Jie Er Yin, Jie Yin Kang) within 72 hours prior to dosing or anticipated use during the trial period;
- •Received antibiotic or antifungal treatment (systemic and/or intravaginal) within 2 weeks prior to dosing;
Arms & Interventions
Vaginal Lactobacillus Dual Probiotic Capsules
Experimental
Intervention: Vaginal Lactobacillus Dual Probiotic Capsules (Drug)
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Clinical Cure Rate
Time Frame: Day 21 to Day 30
Clinical cure is defined as follows: vaginal secretions return to normal physiological secretions; whiff test is negative; clue cells are negative (i.e., the number of clue cells is less than 20% of the total number of vaginal epithelial cells)
Secondary Outcomes
- Bacteriological Cure Rate(Day 21 to Day 30)
- Composite Cure Rate(Day 21 to Day 30)
- Clinical Cure Rate(Day 15 to Day 18)
- Bacteriological Cure Rate(Day 15 to Day 18)
- Composite Cure Rate(Day 15 to Day 18)
- Incidence of treatment-emergent adverse events (Safety Evaluation)(Through study completion, an average of 30 days)
- Incidence of treatment-related adverse events (Safety Evaluation)(Through study completion, an average of 30 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisNCT07314060Chia Tai Tianqing Pharmaceutical Group Co., Ltd.36
Recruiting
Phase 2
Phase II Study of RC1416 Injection in COPDNCT07402551Nanjing RegeneCore Biotech Co., Ltd.180
Not yet recruiting
Not Applicable
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137MindRank AI Ltd738
Recruiting
Phase 2
A Study of Picankibart in Patients With Active Psoriatic ArthritisNCT07295509Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.222
Recruiting
Phase 2
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)NCT07280156Protalix150